Seattle Cellular Therapy Summit: Patient-Centered Approach to Improve Outcomes
This CME-accredited activity, “Seattle Cellular Therapy Summit (SCTS): Patient-Centered Approach to Improve Outcomes”, features leading experts in hematologic malignancies and cellular therapies who will provide a comprehensive overview of current and emerging strategies for the management of lymphoma, myeloma, acute leukemias, and solid tumors with a focus in the use of cellular therapies. The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with hematologic malignancies and to describe potential future applications of cellular therapy in solid tumors. The activity will use a mix of didactic lectures and case-based discussions to highlight areas of debate between cellular therapy and non-cellular therapy in the treatment of these diseases. Expert faculty will aim to place the role of different therapeutic agents in a clinical context and discuss how to utilize these therapeutic options to effectively contribute to patient care.
The symposium will augment healthcare providers’ foundation of knowledge and clinical competence in several areas:
- Providing a review of existing clinical evidence supporting approved Chimeric Antigen Receptor T-cell (CAR T) therapies in the care of patients with B-cell Acute Lymphoblastic Leukemia (B-ALL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), and Multiple Myeloma (MM)
- Describing the role of non-cellular therapies in B-ALL, DLBCL, FL, MCL, and MM
- Identify challenges to the delivery of cellular therapies and provide a discussion on how such barriers may be addressed
- Discussing novel investigational approaches of cellular therapy in acute myeloid leukemias and solid tumors
Target Audience
- Hematologists/Medical Oncologists
- Oncology fellows
- Oncology nurses
- NPs/PAs
- Oncology pharmacists
Hotel Information
Grand Hyatt Seattle
A limited number of rooms have been reserved at the Grand Hyatt Seattle for participants and exhibitors of the Seattle Cellular Therapy Summit at a discounted rate of $249/night for single occupancy. This rate is exclusive of taxes and Seattle Tourism Assessment.
To receive the discounted rate, please reserve your room by Friday, July 14, 2023, by visiting the link below:
Learning Objectives
Upon successful completion of this educational activity, participants will be able to:
- Review indications and outcomes of approved cellular therapies in hematologic malignancies
- Identify emerging CAR-based therapies in hematologic malignancies and solid tumors
- Identify and manage complications after cellular therapy
- Incorporate into practice knowledge about financial toxicity and quality of life after CAR T-cell therapies
- State the financial, physical, and other barriers, review strategies to navigate these factors to optimize the management of patients with cellular therapies
Conference Co-Chairs: Dr. Krish Patel, MD, and Dr. Mazyar Shadman, MD, MPH
(Preliminary schedule)
Day 1 - August 04, 2023
02:30 PM to 03:00 PM Registration, Exhibits, & Networking
03:00 PM to 03:15 PM Welcome & Introductions by co-chairs Dr. Krish Patel & Dr. Mazyar Shadman
03:15 PM to 05:15 PM Session I: Updates on Approved CAR T-Cell Therapies
Moderators: Krish Patel, MD, & Mazyar Shadman, MD, MPH
03:15 PM to 03:40 PM Updates in CAR T-cell Therapy in Lymphoma -David Maloney, MD, PhD
03:40 PM to 04:05 PM Updates in CAR T-cell Therapy in Myeloma -Kumar, Shaji, MD
04:05 PM to 04:30 PM Updates in CAR T-cell Therapy in ALL -Richard Maziarz, MD
04:30 PM to 05:15 PM Panel discussion with Krishna Komanduri, MD, Krish Patel, MD, & Mazyar Shadman, MD, MPH
05:15 PM to 06:15 PM Abstract Session with faculty discussants: Krishna Komanduri, MD, Shaji Kumar, MD, & invited junior faculty (this is a non-CME activity)
Day 2 - August 05, 2023
07:00 AM to 07:55 AM Registration, Breakfast, & Exhibits
08:00 AM to 10:15 AM Session II: Debates in DLBCL and FL
Moderators: Mazyar Shadman, MD, MPH, & Richard Maziarz, MD
08:00 AM to 08:10 AM Case presentation: Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
08:10 AM to 08:25 AM DLBCL debate: CAR T versus Auto-HSCT versus Non-cellular Therapy – in favor of CAR T -Olalekan O. Oluwole, MBBS, MD
08:25 AM to 08:40 AM DLBCL debate: CAR T versus Auto-HSCT versus Non-cellular Therapy – in favor of Auto-HSCT -Mazyar Shadman, MD, MPH
08:40 AM to 08:55 AM DLBCL debate: CAR T versus Auto-HSCT versus Non-cellular Therapy – in favor of Non-cellular Therapy -Tycel Phillips, MD
08:55 AM to 09:10 AM Discussion
09:10 AM to 09:20 AM Case presentation: Relapsed/Refractory Follicular Lymphoma (FL)
09:20 AM to 09:35 AM FL debate: CAR T versus Mosen versus Other – in favor of CAR T -Matthew Ulrickson, MD
09:35 AM to 09:50 AM FL debate: CAR T versus Mosen versus Other – in favor of Mosen -Nadia Khan, MD
09:50 AM to 10:05 AM FL debate: CAR T versus Mosen versus Other –in favor of Other -Chaitra Ujjani, MD
10:05 AM to 10:15 AM Discussion
10:15 AM to 10:30 AM Break & Exhibits
10:30 AM to 12:15 PM Session III: Debates in MCL and Myeloma
Moderators: Nadia Khan, MD, & Krishna Komanduri, MD
10:30 AM to 10:40 AM Case presentation: Relapsed/Refractory Mantle Cell Lymphoma (MCL) -Julia Parker DRNP, AGNP-C
10:40 AM to 10:55 AM MCL debate: CAR T versus BTKi – in favor of CAR T -Matt Lunning, DO
10:55 AM to 11:10 AM MCL debate: CAR T versus BTKi – in favor of BTKi -Alexey Danilov, MD
11:10 AM to 11:20 AM Case presentation: Relapsed/Refractory Multiple Myeloma
11:20 AM to 11:35 AM Myeloma debate: CAR T versus Teclistimab – in favor of CAR T -Swathi Namburi, MD
11:35 AM to 11:50 AM Myeloma debate: CAR T versus Teclistimab – in favor of Teclistimab -Rahul Banerjee, MD
11:50 AM to 12:15 PM Discussion
12:15 PM to 01:15 PM Lunch & Exhibits
01:15 PM to 02:00 PM Session IV: Addressing Barriers to Cellular Therapy
Moderator: TBA
01:15 PM to 01:30 PM Case presentation: Patient Barriers to Cellular Therapy -Samuel Jonas, MSW, and Sonia Glennie, ARNP MSN OCN
01:30 PM to 01:45 PM Allogeneic Cell Therapy: Glimpse of the Future? -Krish Patel, MD
01:45 PM to 02:00 PM Panel discussion with David Aboulafia, MD, Mazyar Shadman, MD, MPH, Krish Patel, MD, & Sherry X. Hu, MD, PhD
02:00 PM to 02:15 PM Break & Exhibits
02:15 PM to 03:30 PM Session V: Cellular Therapy in Leukemias
Moderators: Richard Maziarz, MD, & Melody Smith, MD, MS
02:15 PM to 02:30 PM Bispecific Antibody and CAR T Therapy in ALL - What is the right sequence? -Ryan Cassaday, MD
02:30 PM to 02:45 PM Cellular Therapy in CAR T and CLL -Tanya Siddiqi, MD
02:45 PM to 03:00 PM Cellular Therapy in AML/MDS: Emerging Data -Hany Elmariah, MD
03:00 PM to 03:15 PM Cellular Therapy in AML: Overcoming Challenges -Naval Daver, MD
03:15 PM to 03:30 PM Discussion
03:30 PM to 04:15 PM Session VI: Cellular Therapy in Solid Tumors
Moderator: Sid Devarakonda, MBBS MD
03:30 PM to 03:45 PM Cellular Therapy in Solid Tumors: Emerging Data -Kedar Kirtane, MD
03:45 PM to 04:00 PM Cellular Therapy in Solid Tumors: Overcoming Challenges -Kelly Paulson, MD, PhD
04:00 PM to 04:15 PM Discussion
04:15 PM to 04:20 PM Concluding remarks & announcements
A limited number of rooms have been reserved at the Grand Hyatt Seattle for participants and exhibitors of the Seattle Cellular Therapy Summit at a discounted rate of $249/night for single occupancy. This rate is exclusive of taxes and Seattle Tourism Assessment.
Please reserve your room by Friday, July 14, 2023, by clicking the link below.
https://www.hyatt.com/en-US/
Krish Patel, MD
Mazyar Shadman, MD,MPH
Binay Shah, MD, MHA
Nadia Khan, MD
Krishna Komanduri, MD
Krish Patel, MD
Mazyar Shadman, MD,MPH
Binay Shah, MD, MHA
David Aboulafia, MD
Rahul Banerjee, MD, FACP
Ryan Cassaday, MD
Alexey Danilov, MD, PhD
Naval Daver, MD
Sherry Hu
Samuel Jonas, MSW
Nadia Khan, MD
Kedar Kirtane, MD
Krishna Komanduri, MD
Shaji Kumar, MD
Matthew Lunning, Matt Lunning, D.O., F.A.C.P.
David Maloney, MD, PhD
Swathi Namburi, MD
Krish Patel, MD
Kelly Paulson, MD, PhD
Mazyar Shadman, MD,MPH
Chaitra Ujjani, MD
Available Credit
- 8.75 ABIM MOC IISuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.75 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
- 8.75 AMA PRA Category 1 Credit™The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.75 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
- 8.75 Nursing Contact HoursProvider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.75 Contact Hours.
If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information
Price
REGISTRATION FEES
Physicians (non-industry) - $300
Non-physician HCP (non-industry) - $200
Industry representatives - $1250
NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:
If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:
- If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
- If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event.
Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.
CANCELLATION POLICY
You may cancel your enrollment at any time. Cancellation fees apply as below:
- 50% of the paid registration fee will be refunded if registration is cancelled six weeks before the conference.
- No refunds will be issued if registration is cancelled after that date.
No credits will be offered if you do not complete all required steps of this activity which include registration, participation in the live activity, and completion of pre & post tests as well as course evaluations.